Source:http://linkedlifedata.com/resource/pubmed/id/21033246
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
101
|
pubmed:dateCreated |
2010-10-29
|
pubmed:abstractText |
Very low density lipoprotein receptor (VLDLR) belongs to the low density lipoprotein receptor family, it is divided into two subtypes according to forms with an absence (type II) or a presence (type I) of the O-linked sugar domain. VLDLR have been detected in kinds of cancers so far; however, the subtype of VLDLR in hepatocellular carcinoma (HCC) tissues and hepatoma cell lines has yet to be reported. We detected the VLDLR expression in 39 cases of hepatocellular carcinoma and in three kinds of hepatoma cell lines: HepG2, HBV transfected HepG2.2.15, SMMC-7721 and normal human fetal liver cell line LO2 using RT-PCR and western blotting. The results showed that both type I and type II VLDLR were detected in HCC tissues and hepatoma cell lines, and the type II VLDLR expression was significantly higher than that of type I in cell lines. We inhibited the type II VLDLR expression by shRNA-mediated RNA interference in HepG2, SMMC-7721 cell and then subsequently found the cell proliferation slowed down. The cyclinD1 expression confirmed the cell cycle was arrested at the G0/G1 phase, suggesting that inhibiting the type II VLDLR expression may have a positive impact on carcinogenesis of HCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, VLDL,
http://linkedlifedata.com/resource/pubmed/chemical/Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/methane monooxygenase,
http://linkedlifedata.com/resource/pubmed/chemical/very low density lipoprotein...
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0172-6390
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
57
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
882-90
|
pubmed:meshHeading |
pubmed-meshheading:21033246-Carcinoma, Hepatocellular,
pubmed-meshheading:21033246-Cell Line, Tumor,
pubmed-meshheading:21033246-Cell Proliferation,
pubmed-meshheading:21033246-Cyclin D1,
pubmed-meshheading:21033246-Hep G2 Cells,
pubmed-meshheading:21033246-Humans,
pubmed-meshheading:21033246-Lipoproteins, VLDL,
pubmed-meshheading:21033246-Liver Neoplasms,
pubmed-meshheading:21033246-Oxygenases,
pubmed-meshheading:21033246-RNA, Messenger,
pubmed-meshheading:21033246-RNA Interference,
pubmed-meshheading:21033246-Receptors, LDL
|
pubmed:articleTitle |
Very low density lipoprotein receptor subtype II silencing by RNA interference inhibits cell proliferation in hepatoma cell lines.
|
pubmed:affiliation |
Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|